Where does Faxitron Bioptics, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Faxitron Bioptics, LLC ranks #16,795 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Faxitron Bioptics, LLC hold?

Faxitron Bioptics, LLC holds 17 US utility patents granted between 2018 and 2025, spanning 6 technology areas.

What is Faxitron Bioptics, LLC's Innovation Score?

Faxitron Bioptics, LLC has an Innovation Score of 40.5 out of 100 (top 35% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Faxitron Bioptics, LLC focus on?

Faxitron Bioptics, LLC's top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 14 patents, ranking #1,252 of 7,127 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Faxitron Bioptics, LLC's patent grant rate increasing or decreasing?

Faxitron Bioptics, LLC's recent grant velocity is +333% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Faxitron Bioptics, LLC's patents?

Faxitron Bioptics, LLC's patents average 14.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Faxitron Bioptics, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Faxitron Bioptics, LLC

USPTO PatentsView assignee record - 17 granted patents across 6 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Faxitron ranks #16,795 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 6 technology areas.

#16,795
of 49,997 US assignees by volume: Top 35%
by Innovation Score (40.5/100): 14.3
avg claims per patent: +333%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16795 · US Corporation #16,795 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #16,795/49,997
PHOTO-FINISH FemtoMetrix
CPC-NARROW A61B · 6 areas
INNOV-PAR 40.5/100
CLAIMS-RICH 14.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +333% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: FemtoMetrix, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Faxitron’s 40.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (25%) Velocity 13.3 pts (33%) Breadth 8.7 pts (21%) Claim depth 8.6 pts (21%)

Qualcomm Incorporated · highest

85
Faxitron Bioptics · this assignee

41
3D Lighting… · lowest

7

What this shows Faxitron's Innovation Score is 40.5/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Faxitron?

Each dot is one of Faxitron’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Faxitron’s own 14.3 claims/patent is ABOVE the 11.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Faxitron vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Faxitron's grants concentrate

Faxitron Bioptics, LLC is a focused PatentsView assignee: 6 CPC subclasses with 82.4% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2018. By volume, Faxitron sits between Forta, LLC and ForemostCo., Inc..

Faxitron's three-year grant acceleration

Faxitron Bioptics, LLC shows 10 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Forta

17
FOX Broadcasting

17
Fuse

17
FXS Ventures

17
Femtometrix

17
Florist Holland B…

17
Flower Turbines

17
Foremostco

17
Faxitron Bioptics ◀

17

What this shows Faxitron holds 17 patents at rank #16,806, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Faxitron

By rank, the assignees closest to #16,806 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Faxitron's primary technology class.

Faxitron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Faxitron Bioptics, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	5.9%
2019	2	11.8%
2020	2	11.8%
2021	1	5.9%
2022	5	29.4%
2023	1	5.9%
2024	4	23.5%
2025partial year	1	5.9%

Which technologies does Faxitron Bioptics, LLC patent most?

A61B - DIAGNOSIS; SURGERY; Identification 14

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 9

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 7

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 3

G01T - Measurement OF Nuclear OR X-radiation 3

G06V - Image OR Video Recognition OR Understanding 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Faxitron Bioptics, LLC's patent record in context - here's where to go next.

Faxitron Bioptics, LLC's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 82.4% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #16,795 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Faxitron Bioptics, LLC against Forta, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.